ImmunityBio, Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All IBRX news ›Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement
TradingKey Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement What is driving Immunitybio Inc (IBRX)’s stock price up today? ImmunityBio (IBRX) experienced strong upward price momentum accompanied by…
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) has earned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five…
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’
Shares of ImmunityBio, Inc. (IBRX) climbed about 6% in premarket trading on Tuesday after the Saudi Food and Drug Authority (SFDA) encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin (rBCG), a…
TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance
Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO…
IBRX Stock Extends Rally As Traders Bet On Oncology Momentum
ImmunityBio Inc. surges as pivotal clinical progress drives bullish sentiment, and stocks have been trading up by 7.82 percent. Key Takeaways Shares are up 12.4%, or $1.15, with ImmunityBio trading around $10.43 after a string of…
Immunology and inflammation biotech Bambusa Therapeutics files for a $100 million IPO
BBTX IPO News - Immunology and inflammation biotech Bambusa Therapeutics files for a $100 million IPO Renaissance Capital Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, filed on Friday…
BridgeBio Pharma (BBIO) Receives a Buy from Barclays
In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $156.00. According to TipRanks, Merle is an analyst with an average return of -1.0% and a 36.72% success rate. Merle…
ImmunityBio officer proposes $7.66M share sale
An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX). Stock Titan ImmunityBio officer proposes $7.66M share sale The proposed sale names The Charles Schwab Corporation as broker and NASDAQ as the exchange.…
Immunome (NASDAQ:IMNM) Stock Price Down 6.6% – What’s Next?
Posted by Michael Walen on Oct 8th, 2026 Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares dropped 6.6% during mid-day trading on Tuesday. The company traded as low as $19.84 and last traded at $19.7820. Approximately 448,182 shares…
Autoimmune and inflammatory diseases biotech TRex Bio sets terms for $125 million IPO
TRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio sets terms for $125 million IPO renaissancecapital.com TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, announced terms for its…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
tradingview.com3
-
renaissancecapital.com2
-
stocktwits.com2
-
tradingkey.com2
-
allsci.com1
Measured across the 4WorldWarII news index. Headline tone is a simple word-based reading of the latest 27 headlines, not a forecast.